Osteopore (ASX:OSX) secured a nonexclusive three-year distribution arrangement with Kelyniam Global to market its craniofacial implants in the US, according to a Monday Australian bourse filing.
Working with the medical device manufacturer allows Osteopore to leverage their established access to hospitals and potential customers, its Chief Executive, Yujing Lim, said.
Osteopore expects the first purchase to follow promptly after the agreement is signed.
Its shares rose 7% in recent trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.